cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.15172167
title: Mutation Spectrum Analysis of DMD gene using MLPA method in Indonesian Duchenne and Becker muscular dystrophy patients

description: <b>Background</b>: Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) are allelic disorders caused by mutations in <i>DMD</i> gene. The full mutation spectrum of <i>DMD </i>gene in Indonesian patients is currently unknown. Recently, mutation-specific therapies are being developed, such as exon skipping or stop codon read-through therapy. This study was conducted with the aim of identifying the mutation spectrum of the <i>DMD</i> gene in Indonesia to develop feasible therapeutic applications. <b>Methods</b>: Forty-three male patients with a clinical suspicion of DMD or BMD were enrolled. Multiplex Ligation-Dependent Probe Amplification (MLPA) reaction was performed to screen mutation in the <i>DMD</i> gene. <b>Res</b><b>ults</b>: Out of 43 subjects, deletions accounted for 69.77% (30 cases), while duplications were found in 11.63% (5 cases). Three of the deletion mutations had never been reported before. The remaining 8 patients (18.60%) showed no deletion nor duplication. Out of 31 patients who were genotypically and phenotypically classified as DMD, 26 (60.46%) cases were suitable for exon skipping therapy. <b>Conclusion</b>: This is the first study showing the feasibility of implementing MLPA method in detecting DMD gene mutation in Indonesia. This is also the first study showing the potential application of exon skipping therapy in majority of DMD cases in the country.
DOI: 10.5281/zenodo.5224005
title: DOI's with SDG labels on Target level | 1.4M research articles (2009-2020) related to Sustainable Development Goals

description: Table content: This data set contains 1.4 million publication DOI's related to the Targets of the Sustainable Development Goals in the period 2009 - 2020. Table dimensions: rows: 1.4 million, columns: 4 / rows: 1.4 million, columns: 180 Table columns: doi | date | sdg_target | sdg_goal / doi | date | 169 sdg_targets | 17 sdg_goalsl Table formats: .csv | .xlsx | .parquet <em>How we made this data:</em> We have made a search on Scopus using the Aurora SDG queries version 5 for each of the targets, with a limited year range from 2009 till 2020. Good to know: don't be alarmed if you can find a doi that is labeled with more than one target (~16%). This is not a bug, this is a feature... We used 169 queries, one for each target, a publication can appear in more han one result set. Read this report to learn more about the accuracy of the queries and the data result sets. <em>How can you use this data:</em> You can use this data to 1. quickly match your existing publication lists to this list to see how that your publications are related to the targets of the SDG's. 2. use these as a basis / seed set / gold set to train more advanced text / graph classifiers (after you have extracted title, abstract or even full-text using crossref.org, unpaywall.org, etc) <em>How can you help:</em> Let us know how you use this data. We'll put your project on the list in our SDG matching knowledge base.
description: changes v1.1 added table with unique doi's and sdg_targets and sdg_goals in columns.
DOI: 10.5281/zenodo.5205672
title: DOI's with SDG labels on Target level | 1.4M research articles (2009-2020) related to Sustainable Development Goals

description: Table content: This data set contains 1.4 million publication DOI's related to the Targets of the Sustainable Development Goals in the period 2009 - 2020. Table dimensions: rows: 1.4 million, columns: 4 / rows: 1.4 million, columns: 180 Table columns: doi | date | sdg_target | sdg_goal / doi | date | 169 sdg_targets | 17 sdg_goalsl Table formats: .csv | .xlsx | .parquet <em>How we made this data:</em> We have made a search on Scopus using the Aurora SDG queries version 5 for each of the targets, with a limited year range from 2009 till 2020. Good to know: don't be alarmed if you can find a doi that is labeled with more than one target (~16%). This is not a bug, this is a feature... We used 169 queries, one for each target, a publication can appear in more han one result set. Read this report to learn more about the accuracy of the queries and the data result sets. <em>How can you use this data:</em> You can use this data to 1. quickly match your existing publication lists to this list to see how that your publications are related to the targets of the SDG's. 2. use these as a basis / seed set / gold set to train more advanced text / graph classifiers (after you have extracted title, abstract or even full-text using crossref.org, unpaywall.org, etc) <em>How can you help:</em> Let us know how you use this data. We'll put your project on the list in our SDG matching knowledge base.
description: changes v1.1 added table with unique doi's and sdg_targets and sdg_goals in columns.
DOI: 10.6084/m9.figshare.16697931
title: vLMC meta-data from A dual larynx motor networks hypothesis

description: ALE inputs for vLMC seed. Each block of text provides the coordinates of activation reported in one participant group.
DOI: 10.6084/m9.figshare.16697931.v1
title: vLMC meta-data from A dual larynx motor networks hypothesis

description: ALE inputs for vLMC seed. Each block of text provides the coordinates of activation reported in one participant group.
DOI: 10.6084/m9.figshare.16697934
title: dLMC meta-data from A dual larynx motor networks hypothesis

description: ALE inputs for dLMC seed. Each block of text provides the coordinates of activation reported in one participant group.
DOI: 10.6084/m9.figshare.16697934.v1
title: dLMC meta-data from A dual larynx motor networks hypothesis

description: ALE inputs for dLMC seed. Each block of text provides the coordinates of activation reported in one participant group.
DOI: 10.25934/pr00003485.1
title: Available IPD datapackage for study 'A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).'

description: The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II and III combined), safety, and tolerability of Pramipexole Extended Release (ER) (in daily doses from 0.375mg to 4.5mg q.d.) in comparison to placebo, and to test for non-inferiority between the two formulations (ER and IR) of pramipexole. In addition, the efficacy of Pramipexole Immediate Release (IR) will be compared to placebo, for assay sensitivity
DOI: 10.25934/pr00007143
title: The effects of systemic anti-infective concomitant medications on progression of neurological diseases

description: Various evidence suggests neurological conditions may be induced or exacerbated by microbial infections. Furthermore, it has been shown that anti-infective medications may have neuroprotective properties. A retrospective cohort study was chosen for this research as this will enable me to examine many type of diseases, and many groups of medications, without the need to expose new patients for a new investigation by using existing data. The availability of clinical data from various randomized studies makes such data an attractive source for systematic research on many diseases and many groups of anti-infective medications. I will examine the effect of anti-infective agents on the progression of neurological diseases. Participants from the placebo group in neurological clinical trials who were administered anti-infective drugs for reasons unrelated to the clinical trial will be assessed for changes in their neurological condition and compared with placebo patients not given anti-infectives. These results will elucidate the potential risks and benefits of anti-infective medications for neurological diseases and will assist to better frame their clinical advantages for future clinical trials.
DOI: 10.25934/pr00003482.1
title: Available IPD datapackage for study 'A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).'

description: The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined), safety, and tolerability of pramipexole ER, in daily doses from 0.375 milligram to 4.5 milligram once a day, in comparison to placebo, in Levodopa combined with a Dopa-Decarboxylase-inhibitor treated Parkinson patients with advanced Parkinsons Disease and motor fluctuations. In addition, a numerical comparison of the efficacy of pramipexole extended release versus pramipexole immediate release will be done. The efficacy of pramipexole immediate release will also be compared to placebo, for assay sensitivity.
DOI: 10.5281/zenodo.5566730
title: Machine learning dataset for "Nowcasting thunderstorm hazards using machine learning: the impact of data sources on performance"

description: This repository contains the dataset for the paper: Nowcasting thunderstorm hazards using machine learning: the impact of data sources on performance, Natural Hazards and Earth System Sciences, 2021, https://doi.org/10.5194/nhess-2021-171 For instructions for using the data, please see the code repository here: https://github.com/meteoswiss-mdr/ts-nowcast-datasources
description: This work was supported by the fellowship "Seamless Artificially Intelligent Thunderstorm Nowcasts" from the European Organisation for the Exploitation of Meteorological Satellites (EUMETSAT). The hosting institution of this fellowship is MeteoSwiss in Switzerland.
DOI: 10.6084/m9.figshare.16809970
title: Supplementary Material for: Transcriptome Analysis Identified 2 New lncRNAs Associated with the Metastasis of Papillary Thyroid Carcinoma

description: <b><i>Introduction:</i></b> Papillary thyroid microcarcinoma (PTMC) is a specific subgroup of papillary thyroid carcinoma and defined with the dimension ≤1 cm by the WHO. Although it shows a relatively high 10-year livability, the metastasis of PTMC into other tissues and organs seriously affects the daily life of patients with relatively high mortality. Therefore, the genetic basis for the metastasis of PTMC needs to be explored for effective therapeutic targets. Here, we conducted a series of comparative analysis of the transcriptional expression profile between PTMC patients with and without lymph node metastasis. <b><i>Methods:</i></b> Gene expression profile and gene function were analyzed using RNA extracted from pathological tissues of 12 patients with PTMC, and the core biomarkers closely related to its metastasis were identified. <b><i>Results:</i></b> Our results showed that 7,507 genes and 42 RNAs showed remarkably different expression patterns. More sophisticated analysis showed that the high expression of 2 lncRNAs (T077499 and T004533) resulted in the metastasis of PTMC, which suggests that the expression pattern of the 2 lncRNAs may act as a potential biomarker for pathogenesis and prognosis of PTMC metastasis. <b><i>Conclusion:</i></b> Our findings preliminarily reveal the molecular mechanisms for PTMC metastasis, which will provide vital reference for subsequent studies about the genetic basis and molecular targeted therapy for PTMC metastasis.
DOI: 10.5281/zenodo.5568837
title: Supplementary File_Antibiotics_Risk of Bias Excel Tool (Version 1)

description: Supplementary material (Risk of Bias Excel Tool (Version 1)) for the Cochrane Review "Antibiotics for the treatment of COVID-19".
DOI: 10.5281/zenodo.5568836
title: Supplementary File_Antibiotics_Risk of Bias Excel Tool (Version 1)

description: Supplementary material (Risk of Bias Excel Tool (Version 1)) for the Cochrane Review "Antibiotics for the treatment of COVID-19".
DOI: 10.25934/pr00003463.1
title: Available IPD datapackage for study 'A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.'

description: This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
DOI: 10.5281/zenodo.5506740
title: Code and Data for "Multiple re-reads of single proteins at single-amino-acid resolution using nanopores"

description: The primary structures containing data and analysis products are peptidereads_fig2.mat (for figure 2) and peptiderereads_fig3.mat (for figure 3). The main analysis scripts for these data structures are callvariants_fig2.m and reread_analysis_fig3.m respectively. Data for figures S6 (S6_reread_data.dat) and S8 (S8_hetero_data.dat), and the analysis script used to produce figure S6 (S6_reread_analysis.m) are also included. Other files are dependencies of these main scripts. The fields in peptidereads_fig2 are as follows: <strong>folder, eventnum, reducedStart, reducedEnd, suspicious, hasreread:</strong> notes for internal use <strong>variant:</strong> the true identity of the single-amino-acid substitution variant <strong>data: </strong>the ion current data for each read downsampled to 5 kHz. <strong>omit: </strong>whether the read was omitted from analysis due to length <strong>relativeDNAend</strong>: the index in the data where the DNA portion of the read ends. <strong>relativeLinkerEnd:</strong> the index in the data where the linker portion of the read ends. <strong>DNAlevels, Peplevels, Alllevels:</strong> extracted ion current levels for the DNA region, the peptide region, and everything. <strong>cal: </strong>the multiplicative and additive constants applied to calibrate the read <strong>caldata: </strong>the data with calibration constants applied <strong>cons0D, cons0W, cons0G, cons0DNA: </strong>initial guesses for consensuses based on hand curation of data. <strong>pepDcons0, pepWcons0, pepGcons0:</strong> the portion of the handmade consensus with the variant levels. <strong>pepDcons, pepWcons, pepGcons:</strong> the portion of the iterated consensus with the variant levels. <strong>inhandconsensus: </strong>whether the read was used in generation of the inital guess consensuses. <strong>inconsensus</strong>: whether the read was used in generation of either the initial guess or iterated consensuses. <strong>confidence:</strong> the relative likelihood of each variant assigned to the read <strong>incalls:</strong> whether the data was used in variant calling (i.e., not used in consensus generation) <strong>params</strong>: the analysis parameters used
DOI: 10.5281/zenodo.5506739
title: Code and Data for "Multiple re-reads of single proteins at single-amino-acid resolution using nanopores"

description: The primary structures containing data and analysis products are peptidereads_fig2.mat (for figure 2) and peptiderereads_fig3.mat (for figure 3). The main analysis scripts for these data structures are callvariants_fig2.m and reread_analysis_fig3.m respectively. Data for figures S6 (S6_reread_data.dat) and S8 (S8_hetero_data.dat), and the analysis script used to produce figure S6 (S6_reread_analysis.m) are also included. Other files are dependencies of these main scripts. The fields in peptidereads_fig2 are as follows: <strong>folder, eventnum, reducedStart, reducedEnd, suspicious, hasreread:</strong> notes for internal use <strong>variant:</strong> the true identity of the single-amino-acid substitution variant <strong>data: </strong>the ion current data for each read downsampled to 5 kHz. <strong>omit: </strong>whether the read was omitted from analysis due to length <strong>relativeDNAend</strong>: the index in the data where the DNA portion of the read ends. <strong>relativeLinkerEnd:</strong> the index in the data where the linker portion of the read ends. <strong>DNAlevels, Peplevels, Alllevels:</strong> extracted ion current levels for the DNA region, the peptide region, and everything. <strong>cal: </strong>the multiplicative and additive constants applied to calibrate the read <strong>caldata: </strong>the data with calibration constants applied <strong>cons0D, cons0W, cons0G, cons0DNA: </strong>initial guesses for consensuses based on hand curation of data. <strong>pepDcons0, pepWcons0, pepGcons0:</strong> the portion of the handmade consensus with the variant levels. <strong>pepDcons, pepWcons, pepGcons:</strong> the portion of the iterated consensus with the variant levels. <strong>inhandconsensus: </strong>whether the read was used in generation of the inital guess consensuses. <strong>inconsensus</strong>: whether the read was used in generation of either the initial guess or iterated consensuses. <strong>confidence:</strong> the relative likelihood of each variant assigned to the read <strong>incalls:</strong> whether the data was used in variant calling (i.e., not used in consensus generation) <strong>params</strong>: the analysis parameters used
DOI: 10.25934/pr00006490.0
title: Available IPD datapackage for study 'A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease'

description: The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease
DOI: 10.5281/zenodo.5568845
title: Supplementary File_Antibiotics_Risk of Bias Excel Tool (Version 1)

description: Supplementary material (Risk of Bias Excel Tool (Version 1)) for the Cochrane Review "Antibiotics for the treatment of COVID-19".
DOI: 10.5281/zenodo.5568844
title: Supplementary File_Antibiotics_Risk of Bias Excel Tool (Version 1)

description: Supplementary material (Risk of Bias Excel Tool (Version 1)) for the Cochrane Review "Antibiotics for the treatment of COVID-19".
DOI: 10.5281/zenodo.5562381
title: Precancerous liver diseases do not cause increased mutagenesis in liver stem cells

description: VCF files after variant calling using the HMF pipeline (v4.8) on bam files downloaded from PCAWG as well as from whole genome sequencing of intrahepatic cholangiocyte organoids.
DOI: 10.5281/zenodo.5562380
title: Precancerous liver diseases do not cause increased mutagenesis in liver stem cells

description: VCF files after variant calling using the HMF pipeline (v4.8) on bam files downloaded from PCAWG as well as from whole genome sequencing of intrahepatic cholangiocyte organoids.
DOI: 10.25721/8vr9-fg47
title: Quand j'étais chez mon père, les pattes en haut
DOI: 10.48324/dandi.000008/0.211014.0808
title: Phenotypic variation within and across transcriptomic cell types in mouse motor cortex

description: We used Patch-seq to combine patch-clamp recording, biocytin staining, and single-cell RNA sequencing of over 1300 neurons in adult mouse motor cortex, providing a comprehensive morpho-electric annotation of almost all transcriptomically defined neural cell types. Contained in this dandiset are the intracellular electrophysiological recordings. See Dandiset #35 for an additional dataset, recorded under the physiological temperature.
DOI: 10.48324/dandi.000008/0.211014.0809
title: Phenotypic variation within and across transcriptomic cell types in mouse motor cortex

description: We used Patch-seq to combine patch-clamp recording, biocytin staining, and single-cell RNA sequencing of over 1300 neurons in adult mouse motor cortex, providing a comprehensive morpho-electric annotation of almost all transcriptomically defined neural cell types. Contained in this dandiset are the intracellular electrophysiological recordings. See Dandiset #35 for an additional dataset, recorded under the physiological temperature.
DOI: 10.48324/dandi.000035/0.211014.0808
title: Temperature-controlled intracellular Patch-seq recordings in mouse motor cortex

description:  We used Patch-seq to combine patch-clamp recording, biocytin staining, and single-cell RNA sequencing of over 1300 neurons in adult mouse motor cortex, providing a comprehensive morpho-electric annotation of almost all transcriptomically defined neural cell types. This dataset contains rectangular stimulation of cells under temperature-controlled conditions (34 ℃). See Dandiset #8 for the main dataset, recorded under the room temperature.
DOI: 10.6084/m9.figshare.16810042
title: Raw data from A cross-species framework to identify vocal learning abilities in mammals

description: This document provides the raw acoustic and body mass data used in this study.
DOI: 10.6084/m9.figshare.16810042.v1
title: Raw data from A cross-species framework to identify vocal learning abilities in mammals

description: This document provides the raw acoustic and body mass data used in this study.
DOI: 10.5281/zenodo.5554168
title: Particle size and starch pasting properties analysis as important parameter for new food development by extrusion

description: In the TRUE project, IGV GmbH has started the development and production of various foods from legumes. It was recognized that there are no methods to characterize the processing properties of the raw materials, especially for extrusion. In contrast to the processing of cereals, there is no experience with the functionality of the ingredients. It is not known which ingredients are still of the same quantity and quality. The manufacturers of legume flours and protein products (concentrates, isolates) currently do not offer any corresponding parameters. From own investigations and experiences it is known that parameters like particle size, starch pasting properties, hydration behaviour and the possibility or the ability to agglomerate the ingredients are decisive for the extrusion - but it is not known how this influence affects processing properties. One aim of the work package is to characterize these parameters and their influence of different legume products used for extrusion. This is based on the application of analytical methods which are carried out for the characteristics of cereal products. Finally, extrusion tests were carried out with the samples under standard conditions. Work carried out from 11/2017 to 02/2018 in the labs of IGV.